Abstract
Purpose
Standardized prevalence and incidence data on carbapenem-resistant organisms (CRO) and, as a relevant subgroup, carbapenem-resistant Enterobacteriaceae (CRE) are scarce. CRO-surveillance within the German nosocomial infection surveillance system (KISS) aims to provide epidemiological surveillance data on CRO colonizations and infections.
Methods
CRO-surveillance is part of a KISS-module for the surveillance of multidrug-resistant organisms (MDRO). MDRO-KISS methods require surveillance of all patients admitted to the ward and standardized documentation of imported and ICU-acquired cases. Data on all MDRO-carriers including colonization and infection with MDRO are collected. All presented data were routine data collected from January 1st 2013 until December 1st 2013 in accordance with the German Protection against Infection Act (IfSG).
Results
341 ICUs submitted data on MDRO during the first year. In total, 5,171 cases of multidrug-resistant Gram-negative bacteria (MRGN) were identified. 848 were CRO (16 %). 325 CRO-cases were acquired within the ICU (38 %), and 373 CRO-patients had an infection (44 %). CRO-prevalence was 0.29 per 100 patients. Acquisition rate of MRGN was 1.32 per 1,000 patient days. This rate is more than doubled the acquisition rates of other MDRO under surveillance within MDRO-KISS (0.57 MRSA, 0.49 VRE). CRO-acquisition rate was 0.3 per 1,000 patient days. Incidence density of MRGN infections bacteria was 0.58 per 1,000 patient days (CRO 0.15/1,000 patient days).
Conclusions
To date, CRO are common in German ICUs and the relatively large proportions of ICU-acquired CRO and infections emphasize their potential to cause outbreaks. High MRGN infection rates and high ESBL prevalence data from clinical studies suggest a lack of MRGN identification in asymptomatic carriers.
Similar content being viewed by others
References
Antimicrobial resistance: global report on surveillance 2014. World Health Organization; 2014
Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med. 2010;38:S345–51. doi:10.1097/CCM.0b013e3181e6cbc5.
Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho, F et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930–45. doi:10.1007/s00134-012-2695-9.
Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42:309–16. doi:10.1007/s15010-013-0547-3.
Gastmeier P, Sohr D, Schwab F, Behnke M, Zuschneid I, Brandt C, et al. Ten years of KISS: the most important requirements for success. J Hosp Infect. 2008;70:11–6. doi:10.1016/s0195-6701(08)60005-5.
DIN 58940-4, 4 (2004).
KRINKO. Kommission für Krankenhaushygiene und Infektionsprävention: hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Bundesgesundheitsbl. 2012;55:1311–54.
Infektionsschutzgesetz vom 20. Juli 2000 (BGBl. I S. 1045), das durch Artikel 5 Absatz 2 des Gesetzes vom 20. April 2013 (BGBl. I S. 868) geändert worden ist, Artikel 5 Absatz 2 (2000).
Meyer E, Schroder C, Gastmeier P, Geffers C. The reduction of nosocomial MRSA infection in Germany: an analysis of data from the Hospital Infection Surveillance System (KISS) between 2007 and 2012. Deutsches Arzteblatt int. 2014;111:331–6. doi:10.3238/arztebl.2014.0331.
Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36. doi:10.1016/s1473-3099(09)70054-4.
Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol. 2013;34:144–50. doi:10.1086/669087.
Meyer E, Gastmeier P, Deja M, Schwab F. Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol. 2013;303:388–95. doi:10.1016/j.ijmm.2013.04.004.
Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014;. doi:10.3109/1040841X.2013.875515.
Liss B, Vehreschild J, Cornely O, Hallek M, Fätkenheuer G, Wisplinghoff H, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613–9.
Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846–52.
Ehrhard I, Karaalp AK, Hackel T, Holl G, Rodewald N, Reif U, et al. Prevalence of carbapenemase-producing bacteria in hospitals in Saxony, Germany. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014;57:406–13. doi:10.1007/s00103-013-1914-z.
Heudorf U, Gustav C, Mischler D, Schulze J. Healthcare associated infections (HAI), antibiotic use and prevalence of multidrug-resistant bacteria (MDRO) in residents of long-term care facilities: the Frankfurt HALT plus MDRO project 2012. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2014;57:414–22. doi:10.1007/s00103-013-1927-7.
Lippmann N, Lubbert C, Kaiser T, Kaisers UX, Rodloff AC. Clinical epidemiology of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2014;14:271–2. doi:10.1016/S1473-3099(14)70705-4.
Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro surveillance. 2008;13:19045.
Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC beta-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrobiol Chemother. 2013;68:2092–8. doi:10.1093/jac/dkt136.
ARS. RKI: Antibiotika Resistenz Surveillance. 2014; https://ars.rki.de/Dateneinfuehrung.aspx Accessed 31.07.2014.
Kaase M, Anders A, Pfennigwerth N, Gatermann S. Report of the national reference laboratory for multidrug-resistant gramnegative bacteria on carbapenemases in Germany in 2013. ECCMID; Barcelona 2014.
Maechler F, Schwab F, Geffers C, Gropmann A, Gastmeier P. Infection control policies and ICU-acquired ESBL-cases in Germany: a cross-sectional questionnaire survey of 224 ICUs. ECCMID; Barcelona 2014.
Krankenhausstatistik-Grunddaten [database on the Internet]. Statistisches Bundesamt, Zweigstelle Bonn. 2014; http://www.gbe-bund.de/. Accessed: 27.06.2014.
Zuschneid I, Rucker G, Schoop R, Beyersmann J, Schumacher M, Geffers C, et al. Representativeness of the surveillance data in the intensive care unit component of the German nosocomial infections surveillance system. Infect Control Hosp Epidemiol. 2010;31:934–8. doi:10.1086/655462.
Acknowledgments
We thank all nurses and physicians in the participating hospitals who provided their MDRO data to KISS. Data have been generated as part of the routine work of the nosocomial infection surveillance system (NRZ KISS).
Conflict of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maechler, F., Peña Diaz, L.A., Schröder, C. et al. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection 43, 163–168 (2015). https://doi.org/10.1007/s15010-014-0701-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-014-0701-6